|
Luis, first of all I apologize for not replying sooner, I never saw the message until today. I have gotten caught up in other "things". Today, being approximately a month since the settlement was announced to the public, FONR has continued to slowly but surely decline. It definitely has potential...nothing has changed, yet, many investors again have grown impatient (understandably so for many). In regards to your questions, there are many selling points in regards to FONR's products, I suggest that you visit their website and/or read up on some of the doctors' exchanges on this thread. For me, what sells is that FONR's products are better than the competitions' and they are, in many cases more affordable/practical than what is presently out there. Fonar's sales team has to take that kind of an angle if they are to be successful in landing contracts. The QUAD 12000 is a top of the line product that in the end will save hospitals and clinics thousands and thousands of dollars in the future and give them better images than what are presently being produced by present MRIs. Either way, it still adds up to FONAR having better products than the rest, but that doesn't always amount to stock price and investor acceptance. Again, for a clearer and more precise explanation, read up on the thread...sorry, this is the best I could do with limited time. |
